Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company ...

A preliminary modeling study suggests that four variables accessible at discharge could predict the risk for 90-day ...

JACK FITZWATER has revealed how he thought his football career was in jeopardy when he was forced to visit the toilet 40 times a day. The defender hopes to help League One club Exeter topple ...

Palisade Bio (PALI) announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific ...

To present the pioneering concept, Peer and his team encoded the anti-inflammatory protein interleukin-10 into mRNA and ...

Dr. Saward is an accomplished biotechnology executive with more than 25 years of experience in therapeutic drug development from preclinical to licensure. She will lead Synedgen’s scientific strategy ...

No significant difference in the risk for MACE was observed between patients with IBD receiving JAK vs TNF inhibitors.

Clinical trials help researchers studying chronic conditions answer important questions about the diseases and their treatment options. However, uncertainty about what to expect and a lack of ...

Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...

SAN FRANCISCO -- Janus kinase (JAK) inhibitors appeared to be a safe, effective option for treating inflammatory bowel ...

Dr. Gunn added, “Given QBECO SSI’s novel immunological mechanism and the growing interest in the role of senescence in the progression of aging and chronic disease, these data suggest that clearing ...

A systematic review finds that following the Mediterranean diet is linked to better physical, mental, and social well-being, ...